-
Israel court extends detention of two Gaza flotilla activists
-
Massive search continues for two missing US soldiers in Morocco
-
Players keep up battle with tennis majors as they decry Roland Garros prize money
-
Pistons rout Magic to complete comeback, advance in NBA playoffs
-
Trump says US and Iran in 'positive' talks, unveils plan to escort Hormuz ships
-
Talisman Endrick fires resurgent Lyon into third in France
-
Verstappen laments spin and struggle for pace in Miami
-
Teen Antonelli wins again in Miami to extend title race lead
-
Ferrari's Leclerc admits he threw away Miami podium finish
-
Cristian Chivu, a winner with Inter on the pitch and in the dugout
-
Key players from Inter Milan's Serie A title triumph
-
No.4 Young cruises to PGA title at Doral
-
Vinicius double delays Barca title as Real Madrid down Espanyol
-
Inter Milan win Italian title for third time in six seasons
-
Spurs solved mental frailty to boost survival bid: De Zerbi
-
Miami champ Antonelli shrugs off success, vows 'back to work'
-
Man Utd beat Liverpool, Spurs climb out of relegation zone
-
Spurs out of relegation zone after vital win at Villa
-
No.1 Korda cruises to LPGA Mexico crown
-
Thompson-Herah shines at world relays, Tebogo helps Botswana to win
-
Three die on Atlantic cruise ship from suspected hantavirus: WHO
-
Germany's Merz says not 'giving up on working with Donald Trump'
-
Mercedes' Kimi Antonelli wins Miami Grand Prix
-
Man Utd job feels 'natural' to Carrick
-
Ferguson taken to hospital before Man Utd win against Liverpool
-
'Devil Wears Prada 2' takes top spot in N. America box office
-
Iran weighs US response to peace plan after warning against military action
-
Gladbach sink Dortmund, St Pauli edge closer to drop
-
Rubio to visit Rome, meet Pope Leo after Trump row
-
Kyiv hits Russian oil sites as eight killed in both countries
-
Iran says US military operation 'impossible' as Trump mulls peace proposal
-
Man Utd beat Liverpool to secure Champions League place
-
Two die in 'respiratory illness' outbreak on Atlantic cruise ship
-
Barcelona sink Bayern to reach women's Champions League final
-
True Love lands eighth English 1000 Guineas for O'Brien
-
Sinner dismantles Zverev to win Madrid Open, set record
-
Brilliant Bordeaux clean out Bath to reach Champions Cup final
-
Second unexploded shell found at illegal French rave: minister
-
Bournemouth eye European place after crushing Palace
-
Pogacar ends dominant Tour of Romandie with fourth win
-
Chakravarthy, Narine help Kolkata stay alive in IPL
-
Daughter says Maradona died after carers' plan 'went out of control'
-
Two women suffocate on migrant boat seeking to reach UK
-
How Schalke returned to the Bundesliga after their 'worst season ever'
-
Two women die on migrant boat seeking to reach UK
-
Mumbai coach Jayawardene backs Suryakumar to find his 'rhythm'
-
Under full moon, Shakira thrills 2 million fans on Rio's Copacabana beach
-
Bangkok food vendor curbs push city staple from the streets
-
More Nepalis drive electric, evading global fuel shocks
-
Latecomer Japan eyes slice of rising global defence spending
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share.
"We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth," said Joseph Dowling, CEO of CV Sciences. "This is a transformative step for our Company in strengthening our balance sheet and positioning the Company for sustained profitability. This transaction better equips us to deliver value to our customers, partners and shareholders, while pursuing new opportunities with confidence."
CV Sciences has recently launched Empowr, a plant-based protein and creatine formula designed for total wellness. With this launch, CV Sciences has continued to expand its growing portfolio of innovative wellness solutions under its +PlusHLTH™, Happy Living Through Health, cannabinoid-free supplement line. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the +PlusHLTH line delivers targeted formulations for optimized health, improved performance, and increased vitality. For more information, please visit https://www.pluscbdoil.com/plushlth.html or https://www.cvsciences.com/.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ subsidiary specializes in contract manufacturing and branded products for the nutraceutical and plant-based food industries, with distribution primarily across the EU and select international markets. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Forward Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.
Contact Information
[email protected]
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
S.Gregor--AMWN